AgomAb Therapeutics NV (AGMB)
12.14
+0.06
(+0.50%)
USD |
NASDAQ |
Sep 18, 16:00
12.14
0.00 (0.00%)
After-Hours: 19:50
AgomAb Therapeutics Enterprise Value : 459.55M for Sept. 17, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 17, 2026 | 459.55M |
| September 16, 2026 | 426.55M |
| September 15, 2026 | 463.49M |
| September 14, 2026 | 469.40M |
| September 11, 2026 | 507.81M |
| September 10, 2026 | 551.15M |
| September 09, 2026 | 601.38M |
| September 08, 2026 | 598.92M |
| September 04, 2026 | 641.77M |
| September 03, 2026 | 594.98M |
| September 02, 2026 | 537.36M |
| September 01, 2026 | 531.45M |
| August 31, 2026 | 513.23M |
| August 28, 2026 | 513.23M |
| August 27, 2026 | 546.23M |
| August 26, 2026 | 567.89M |
| August 25, 2026 | 555.09M |
| August 24, 2026 | 495.99M |
| August 21, 2026 | 517.17M |
| August 20, 2026 | 526.03M |
| August 19, 2026 | 541.79M |
| August 18, 2026 | 540.81M |
| August 17, 2026 | 538.35M |
| August 14, 2026 | 515.69M |
| August 13, 2026 | 551.40M |
| Date | Value |
|---|---|
| August 12, 2026 | 559.52M |
| August 11, 2026 | 595.97M |
| August 10, 2026 | 603.35M |
| August 07, 2026 | 578.73M |
| August 06, 2026 | 529.48M |
| August 05, 2026 | 569.86M |
| August 04, 2026 | 590.06M |
| August 03, 2026 | 530.47M |
| July 31, 2026 | 498.45M |
| July 30, 2026 | 492.79M |
| July 29, 2026 | 475.31M |
| July 28, 2026 | 482.20M |
| July 27, 2026 | 480.73M |
| July 24, 2026 | 480.73M |
| July 23, 2026 | 503.38M |
| July 22, 2026 | 435.91M |
| July 21, 2026 | 437.88M |
| July 20, 2026 | 454.62M |
| July 17, 2026 | 457.58M |
| July 16, 2026 | 471.37M |
| July 15, 2026 | 486.64M |
| July 14, 2026 | 457.58M |
| July 13, 2026 | 470.88M |
| July 10, 2026 | 508.80M |
| July 09, 2026 | 506.33M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 14.82M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| GB Sciences, Inc. | -- |
| Invion Ltd. | -- |
| Arvinas, Inc. | -17.06M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.25M |
| Total Expenses (Quarterly) | 20.25M |
| EPS Diluted (Quarterly) | -0.4156 |
| Earnings Yield | -5.54% |